gefitinib has been researched along with Paronychia in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Daroach, M; Kumaran, MS; Thakur, V | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Byun, SY; Choi, JW; Hong, JS; Huh, CH; Kwon, SH; Na, JI; Park, KC; Youn, SW | 1 |
| Nakamura, M; Nakano, J | 1 |
| Dainichi, T; Furue, M; Noda, K; Tanaka, M; Tsuruta, N | 1 |
| Choi, JH; Kim, SW; Koh, JK; Lee, HW; Lee, MW; Moon, KC; Seo, CW; Yang, HJ | 1 |
| Chang, GC; Chen, KC; Lin, YC; Wang, RC; Yang, TY; Yin, MC | 1 |
| Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO | 1 |
1 review(s) available for gefitinib and Paronychia
| Article | Year |
|---|---|
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
9 other study(ies) available for gefitinib and Paronychia
| Article | Year |
|---|---|
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
Papulopustules and paronychia in a lung carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Syndrome | 2019 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Gefitinib-induced paronychia: response to autologous platelet-rich plasma.
Topics: Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Paronychia; Platelet-Rich Plasma; Quinazolines | 2012 |
Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Aged; Aged, 80 and over; Biopsy, Needle; Enzyme Inhibitors; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Topics: Acneiform Eruptions; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Retrospective Studies; Signal Transduction; Skin; Urticaria | 2004 |
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Hyperpigmentation; Lung Neoplasms; Middle Aged; Paronychia; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2007 |